Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

Inclusion Criteria: * Histologically or cytologically diagnosis of metastatic ductal adenocarcinoma of the pancreas. * No prior radiotherapy, surgery chemotherapy or investigational therapy for metastatic disease. Prior adjuvant therapy with 5-FU or gemcitabine (± gemcitabine post radiation) administered as radiosensitizer allowed, provided at least 6 months have elapsed between the last dose and study registration * Tumor tissue available (Archival 6 months old or de novo biopsy) * Measurable disease as per RECIST 1.1 * Performance Status (ECOG) 0 or 1 Exclusion Criteria: * Symptomatic brain metastases requiring steroids * Prior therapy with gamma secretase inhibitors or other Notch pathway inhibitor * Major surgery within 4 weeks of registration in the current study * Known hypersensitivity to gemcitabine or nab-paclitaxel or any of the excipients * Current or anticipated need for food or drugs that are strong/moderate CYP3A4 inhibitors or inducers * Diagnosis of any second malignancy within 3 years prior to registration